--- schema_version: "secwatch.filing_event.v1" accession: "0000816956-26-000057" form_type: "8-K" ticker: "CNMD" cik: "0000816956" company_name: "CONMED Corp" filed_at: "2026-05-20T12:30:27+00:00" generated_at: "2026-05-20T12:37:10.948108+00:00" event_type: "leadership" sentiment: "positive" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # CONMED appoints two new directors from J&J and Boston Scientific; Board expands to nine ## Summary - Appointed Celine Martin (ex-J&J MedTech exec) and Jeff Mirviss (ex-Boston Scientific exec) to Board, effective July 1, 2026. - Martin to serve on Audit and Strategy Committees; Mirviss on Compensation and Governance Committees. - Appointed Kimberly Lockwood as Interim Corporate Controller and Principal Accounting Officer, effective June 1, 2026. - Stockholders elected seven directors, approved say-on-pay, and ratified PwC as auditor for fiscal 2026. ## SEC filing metadata - accession: 0000816956-26-000057 - form_type: 8-K - ticker: CNMD - cik: 0000816956 - company_name: CONMED Corp - filed_at: 2026-05-20T12:30:27+00:00 - event_type: leadership - sentiment: positive - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 5.02, 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/cnmd-20260518.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000816956-26-000057 - JSON: https://secwatch.observer/filing/0000816956-26-000057.json - Plain text: https://secwatch.observer/filing/0000816956-26-000057.txt ## Key facts - Executive change Jeff Mirviss was appointed as Director at CONMED Corp. - Action: appointed - Role: Director source text: On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm - Executive change Kimberly Lockwood was appointed as Interim Corporate Controller and Interim Principal Accounting Officer at CONMED Corp. - Action: appointed - Role: Interim Corporate Controller and Interim Principal Accounting Officer source text: On May 19, 2026, the Board appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer of the Company effective June 1, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm - Executive change Celine Martin was appointed as Director at CONMED Corp. - Action: appointed - Role: Director source text: On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm - Governance Changes CONMED Corp: Amended and restated bylaws to update advance notice provisions, including timeframe for stockholder notices (90 to 120 days before anniversary of prior annual meeting), director interview requirement, and ministerial changes (effective 2026-05-19). - Change: bylaw amendment - Effective: 2026-05-19 source text: On May 19, 2026, the Board adopted and approved the amended and restated by-laws of the Company (the "By-laws") to, among other things, make updates to reflect developments in Delaware law and current market practice, update the Company's advance notice provisions regarding stockholder nominations of directors and submissions of proposals regarding other business, including to modify the permissible timeframe for receipt of stockholder notices to 90 to 120 days prior to the first anniversary of the date of the annual meeting of stockholders for the preceding year, require that, to be eligible to serve as a director, candidates must make themselves available to be interviewed by the Board (or any committee or other subset thereof) and make ministerial and conforming changes. evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm - Shareholder Votes CONMED Corp shareholders approved Advisory vote on the compensation of our named executive officers at the 2026-05-18 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-05-18 source text: 2. The advisory vote on the compensation of our named executive officers was approved. Shares For Against Abstain Broker Non-Votes 26,230,404 1,742,683 26,798 939,351 evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm - Shareholder Votes CONMED Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2026 at the 2026-05-18 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-05-18 source text: 3. The ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2026 was approved. Shares For Against Abstain Broker Non-Votes 27,295,501 1,636,906 6,829 0 evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm - Shareholder Votes CONMED Corp shareholders approved Election of seven directors at the 2026-05-18 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-05-18 source text: At the Company’s annual meeting of stockholders held on May 18, 2026, stockholders voted on three proposals and the final voting results are set forth below. 1. The following table sets forth the seven persons elected to serve until the 2027 annual meeting of stockholders and until a respective successor has been duly elected and qualified, or until such director’s earlier termination of service. Shares Name For Withhold Broker Non-Votes Patrick J. Beyer 27,649,816 350,069 939,351 David Bronson 27,509,362 490,523 939,351 LaVerne H. Council 27,291,818 708,067 939,351 Charles M. Farkas 26,103,593 1,896,292 939,351 Mark Kaye 27,680,526 319,359 939,351 Kim Kelderman 27,663,316 336,569 939,351 Barbara J. Schwarzentraub 27,566,345 433,540 939,351 evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/0000816956-26-000057-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.